4 articles | last updated: May 16 14:56:00
The Biosecure Act seeks to reduce dependence on Chinese biotech companies over national security concerns, moving through Congress with bipartisan support.
- The House Committee on Oversight and Accountability approved the Biosecure Act 40-1.
- The bill aims to restrict US business with BGI, WuXi AppTec, WuXi Biologics, and other Chinese biotech firms.
- US companies have until 2032 to end contracts with the targeted Chinese firms.
- The legislation also bans federal agencies from using equipment or services from these companies.
- Chinese biotech firms argue the bill is based on false allegations and would harm competition.
People, Places and Things In This Story
- WuXi Biologics Pharmaceutical company
- United States Country in North America
- BGI Group Biotechnology company
- China Country in East Asia
- House Committee on Oversight and Government Reform Legislative committee
- WuXi AppTec Pharmaceutical company
- United States Congress Governing body
Categories:
- Business
- Politics
- Health
- Government
- Society